

## Special Issue

# Neoadjuvant Therapy for Pancreatic Cancer

### Message from the Guest Editor

Pancreatic cancers, including adenocarcinoma and its subtypes, remain among the most dreadful malignancies, plagued by limited innovations, typically late diagnoses, and significant heterogeneity. Recent randomized trials have demonstrated the efficacy of chemotherapy-first approaches in resectable PDAC, but the optimal selection criteria for patients best suited to this strategy remain unclear. In neoadjuvant treatment strategies, carefully choosing the most effective induction therapy and minimizing side effects are critical to ensuring effectiveness without delaying or compromising surgical intervention. A key knowledge gap in neoadjuvant treatment lies in the absence of validated biomarkers to guide NCT decision making.

For this Special Issue of *Cancers*, we invite original research and review articles that highlight recent advancements and future challenges in improving neoadjuvant strategies for pancreatic cancer management.

---

### Guest Editor

Dr. Brice Chanez

Department of Medical Oncology, Institute Paoli-Calmettes, 13009 Marseille, France

---

### Deadline for manuscript submissions

closed (30 March 2026)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/229497](https://mdpi.com/si/229497)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)